Verrica Pharmaceuticals Inc. (VRCA) stock
VRCANasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.85−0.29 (-9.08%)
Close on Nov 18, 2026Market cap $49.05MP/E –Yield –
Verrica Pharmaceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Verrica Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $30.32M, up 106.2% year over year. For fiscal 2025 it was $35.58M, up 370.2% from the year before. The highest annual figure on record is $35.58M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.58M | +370.2% |
| FY2024 | Dec 31, 2024 | $7.57M | +47.7% |
| FY2023 | Dec 31, 2023 | $5.12M | -43.3% |
| FY2022 | Dec 31, 2022 | $9.03M | -24.7% |
| FY2021 | Dec 31, 2021 | $12.00M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $5.86M | -53.8% |
| Q1 FY2026 | Mar 31, 2026 | $5.02M | +46.1% |
| Q4 FY2025 | Dec 31, 2025 | $5.09M | +1380.2% |
| Q3 FY2025 | Sep 30, 2025 | $14.34M | – |
| Q2 FY2025 | Jun 30, 2025 | $12.70M | +145.4% |
| Q1 FY2025 | Mar 31, 2025 | $3.44M | -10.1% |
| Q4 FY2024 | Dec 31, 2024 | $344.00K | -82.7% |
| Q3 FY2024 | Sep 30, 2024 | -$1.78M | -161.1% |
| Q2 FY2024 | Jun 30, 2024 | $5.18M | +2744.5% |
| Q1 FY2024 | Mar 31, 2024 | $3.83M | +10240.5% |
| Q4 FY2023 | Dec 31, 2023 | $1.99M | +2823.5% |
| Q3 FY2023 | Sep 30, 2023 | $2.92M | -64.9% |
| Q2 FY2023 | Jun 30, 2023 | $182.00K | -15.0% |
| Q1 FY2023 | Mar 31, 2023 | $37.00K | -91.4% |
| Q4 FY2022 | Dec 31, 2022 | $68.00K | – |
| Q3 FY2022 | Sep 30, 2022 | $8.32M | – |
| Q2 FY2022 | Jun 30, 2022 | $214.00K | – |
| Q1 FY2022 | Mar 31, 2022 | $431.00K | -96.4% |
| Q4 FY2021 | Dec 31, 2021 | $0 | – |
| Q3 FY2021 | Sep 30, 2021 | $0 | – |
| Q2 FY2021 | Jun 30, 2021 | $0 | – |
| Q1 FY2021 | Mar 31, 2021 | $12.00M | – |
See a number that looks wrong?